

DAFTAR PUSTAKA

- Baek, S.C., Choi, B., Nam, S.-J., & Kim, H., 2018, Inhibition of monoamine oxidase A and B by demethoxycurcumin and bisdemethoxycurcumin, *Journal of Applied Biological Chemistry*, **61**(2), 187-190.
- Da'i, M., Wulandari, R., Utami, M., 2001, Uji Aktivitas Penangkapan Radikal DPPH Analog Kurkumin Siklik dan N-heterosiklik monoketon, *Pharmakon*, 12(1), 19–25.
- Dei Cas, M., & Ghidoni, R., 2019, Dietary curcumin: correlation between bioavailability and health potential, *Nutrients*, 11(9), 2147.
- Dar, A.M., dan Mir, S., 2017, Molecular Docking: approaches, Types, Applications, and Basic challenges, *Journal of Analytical & Bioanalytical Techniques*, 8(2), 1-3.
- DiMasi, J. A., Grabowski, H. G., & Hansen, R. W., 2016, Innovation in the pharmaceutical industry: New estimates of R&D costs, *Journal of health economics*, 47, 20–33.
- Goel, A., Kunnumakkara, A.B., Aggarwal, B.B., 2008, Curcumin as “curecumin”: from kitchen to clinic. *Biochem. Pharmacol.* 75, 787–809.
- Gupta, N. K., & Dixit, V. K., 2011, Bioavailability enhancement of curcumin by complexation with phosphatidyl choline, *Journal of Pharmaceutical Sciences*, 100, 1987-1995.
- Hakim, A.R., Hakim, L., Margono, S.A., 2003, Pengaruh Pentagamavunon-0 terhadap Farmakokinetika Teofilin pada Tikus, *Majalah Farmasi Indonesia*, 14(1), 244-249.
- Hakim, A.R., Nugroho, A.E., Hakim, L., 2006, Profil farmakokinetika pentagamavunon-0 setelah pemberian kalium pentagamavunon-0 secara oral pada tikus, *Majalah Farmasi Indonesia*, 17(4), 204-211.
- Hassaninasab, A., Hashimoto, Y., Tomita-Yokotani, K., & Kobayashi, M., 2011, Discovery of the curcumin metabolic pathway involving a unique enzyme in an intestinal microorganism. *Proceedings of the National Academy of Sciences of the United States of America*, 108(16), 6615–6620.
- Ireson, C. R., Jones, D. J., Orr, S., Coughtrie, M. W., Boocock, D. J., Williams, M. L., & Gescher, A. J., 2002, Metabolism of the cancer chemopreventive agent curcumin in human and rat intestine, *Cancer Epidemiology Biomarkers & Prevention*, 11(1), 105-111.
- Iyanagi, T., 2007, Molecular mechanism of phase I and phase II drug-metabolizing enzymes: implications for detoxification, *International review of cytology*, 260, 35-112.
- Jančová, P. dan Šiller, M., 2012, Phase II drug metabolism. *Topics on drug metabolism*, 35-60.
- Kitchen, D.B., Decornez, H., Furr, John R., & Bajorath, J., 2004, *Docking and scoring in Virtual Screening for Drug Discovery: Methods and Applications*, Nat. Rev. 3, 935–949.
- Kuttan, R., Bhanumathy, P., Nirmala, V. G., Padmanaban, G., Rangarajan, P. N., 2005, Curcumin for malaria therap., *Biochem Biophys. Res. Commun.*, 326(2), 472-4.
- Kunnumakkara, A. B., Bordoloi, D., Padmavathi, G., Monisha, J., Roy, N. K., Prasad, S., & Aggarwal, B. B., 2017, Curcumin, the golden nutraceutical: multitargeting for multiple chronic diseases, *British journal of pharmacology*, 174(11), 1325–1348.
- Mahady, G. B., Pendland, S. L., Yun, G., Lu, Z. Z., 2002, Turmeric (*Curcuma longa*) and

- curcumin inhibit the growth of *Helicobacter pylori*, a group 1 carcinogen. *Anticancer Res.* 22 (6C),4179-81.
- Meng, X.Y., Zhang, H.X., Mezei, M., & Cui, M., 2011, Molecular docking: A powerful approach for structure-based drug discovery, *Curr.Comp-Aided Drug Des.* 7(2),146–157.
- Oetari, R.A., Sardjiman, Yuwono, T., dan Hakim, L., 2001, Upaya Peningkatan Absorpsi Senyawa Baru Antiinflamasi PGV-0, *Laporan Penelitian Hibah Bersaing IX/1 Perguruan Tinggi*, Lembaga Penelitian Universitas Gadjah Mada, 17
- Priyadarsini, K.I., 2014, The chemistry of curcumin: from extraction to therapeutic agent, *Molecules*, 19(12), 20091– 20112.
- Ravindranath, V., Chandrasekhara, N., 1981, In vitro studies on the intestinal absorption of curcumin in rats. *Toxicology*, 20 (2-3), 251-257.
- Rester, U., 2008, *From virtual to reality - Virtual screening in lead discovery and lead optimization: a medicinal chemistry perspective. Current Opinion in Drug Discovery & Development*, **11**: 559 – 568.
- Sahne, F., Mohammadi, M., Najafpour, G.D., Moghadamnia, A.A., 2017, Enzyme-assisted ionic liquid extraction of bioactive compound from turmeric (*Curcuma longa* L.): isolation, purification and analysis of curcumin. *Ind. Crops Prod.* 95, 686–694.
- Sardjiman, S., Reksohadiprodjo, M.S., Hakim, L., H Van der Goot., H Timmermen. 1997, 1,5- Diphenyl-1,4-pentadiene-3-ones and cyclic analogues as antioxidative agents. Synthesis and structure-activity relationship. *European Journal of Medicinal Chemistry*, 32(7-8), 625-630.
- Sharma, R.A., Gescher, A.J., Steward, W.P., 2005, Curcumin: The Story so far, *European Journal of Cancer*, 41, 1955-1968.
- Teo, Y. L., Ho, H. K., & Chan, A., 2015, Metabolism-related pharmacokinetic drug-drug interactions with tyrosine kinase inhibitors: current understanding, challenges and recommendations. *British journal of clinical pharmacology*, 79(2), 241–253.
- Wahlstrom, B., & Blennow, G., 1978, A study on the fate of curcumin in the rat. *Acta pharmacologica et toxicologica*, 43(2), 86-92.
- Yixuan, L., Qaria, M.A., Sivasamy, S., Jianzhong, S., Daochen, Z., 2021, Curcumin production and bioavailability: A comprehensive review of curcumin extraction, synthesis, biotransformation and delivery systems, *Industrial Crops and Products*, 172,114050.
- Yoysungnoen, P., Wirachwong, P., Changtam,C., Suksamrarn, A., & Patumraj S., 2008, Anti-cancer and anti-angiogenic effects of curcumin and tetrahydrocurcumin on implanted hepatocellular carcinoma in nude mice. *World Journal of Gastroenterology*, 14, 2003-2009
- Zhang, Z., Tang, W., 2018, Drug Metabolism in Drug Discovery and Development. *Acta Pharm Sinica. B*, 8(5), 721–732.
- Zhou, S. F., Zhong, W. Z., 2017, Drug Design and Discovery: Principles and Applications, *Molecules*, 22(2), 279.